Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

A Study Of Celecoxib Versus Diclofenac In Patients With Ankylosing Spondylitis

18. august 2015 opdateret af: Pfizer

A Twelve Week, Randomized, Double Blind Parallel Group Study Of Two Doses Of Celecoxib Compared To Diclofenac In Patients With Ankylosing Spondylitis

A clinical trial to assess the effect of celecoxib 200 milligrams (mg) once daily and 400 milligrams (mg) once daily compared to diclofenac three times daily in the treatment of Ankylosing Spondylitis (AS) for 12 weeks. This will be used to confirm the results of a prior 6 week trial.

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

330

Fase

  • Fase 4

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

  • Norge
      • Bekkestua, Norge, 1357
        • Bekkestua legesenter
      • Bergen, Norge, 5004
        • Dr. Johannessen Kontor
      • Bergen, Norge, 5838
        • Dr.Wiigs kontor
      • Bodø, Norge, 8006
        • Nordland Medisinske Senter
      • Bærum Postterminal, Norge, 1306
        • Martina Hansens Hospital
      • Drammen, Norge, 3004
        • Sykehuset Buskerud HF
      • Gamle Fredrikstad, Norge, 1632
        • Lægene på Kongens torv
      • Hamar, Norge, 2300
        • Centre For Clinical Trials
      • Harstad, Norge, 9480
        • Harstad sykehus
      • Haugesund, Norge, 5513
        • Haugesund sanitetsforenings revmatismesykehus
      • Horten, Norge, 3188
        • Horten legesenter
      • Jessheim, Norge, 2050
        • Solli Klinikk AS
      • Kongsvinger, Norge, 2226
        • Kongsvinger sykehus HF
      • Kristiansand, Norge, 4604
        • Vest-Agder sentralsykehus
      • Kristiansand, Norge, 4610
        • Dr. Svensens kontor
      • Lena, Norge, 2850
        • Lensbygda Legekontor
      • Levanger, Norge, 7600
        • Helse Nord-Trøndelag HF, Sykehuset Levanger
      • Lillehammer, Norge, 2609
        • LSF Reumatismesykehus
      • Mo I Rana, Norge, 8607
        • Helgelandssykehuset HF
      • Oslo, Norge, 0027
        • Rikshospitalet
      • Oslo, Norge, 0580
        • Økernlegene
      • Oslo, Norge, N-0319
        • Diakonhjemmet Hospital
      • Skien, Norge, 3722
        • Betanien Hospital
      • Tiller, Norge, 7092
        • Rosten legesenter
      • Tromsø, Norge, 9038
        • Universitetssykehuset Nord-Norge HF
      • Trondheim, Norge, 7006
        • St.Olavs Hospital
      • Ålesund, Norge, 6026
        • Ålesund sykehus

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 75 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Male or female, 18 to 75 years of age, inclusive.
  • Clinical diagnosis of ankylosing spondylitis:
  • Willing to stop existing NSAID/COX-2 inhibitor treatment for up to two weeks.
  • Having given written informed consent to participate in the trial.
  • Pain intensity ≥ 40 mm on the visual analog scale, worsening by at least 30 % compared to that recorded at the screening visit.
  • Last administration of analgesic without anti-inflammatory activity is ≥ 8 h, the last administration of long-acting NSAIDs is ≥ 72 h

Exclusion Criteria:

  • Patients with acute peripheral articular disease (defined by the onset within 4 weeks prior to visit
  • Known inflammatory enteropathy (e.g. ulcerative colitis, Crohn's disease).
  • Ongoing extra-articular signs (e.g. cardiac involvement).
  • Current painful vertebral compression.
  • Requirement to start physiotherapy, re-education or manipulation
  • History of clinical gastroduodenal ulcer in the year preceding inclusion, confirmed by endoscopy; continuing gastro-intestinal bleeding.
  • Cardiac failure or known renal insufficiency that could be affected by study medication, chronic or acute hepatic insufficiency, significant coagulation disorders or history of asthma.
  • Current or history of malignancy (except: patients having a basal cell carcinoma or other malignancy operated on and in remission for 5 years before inclusion in the trial).
  • Pregnancy, women of childbearing potential not using adequate contraceptive methods or nursing mothers.
  • Subject who has evidence of alcohol or drug abuse.
  • Participation in any other clinical study within 30 days prior to the screening visit.
  • Any condition that would prevent the patient from entering the study, according to the investigator's judgment.
  • Known hypersensitivity to celecoxib, sulphonamides or any NSAID (including salicylic acid).
  • Taking the following medications: Muscle relaxants, hypnotic, anxiolytics, sedatives, tranquillizers or antidepressants (unless stable for 2 weeks before screening and continuing throughout the trial), NSAIDs or COX-2 inhibitors other than study medication, acetylsalicylic acid (ASA) > 160 mg /day, anti-coagulants, ticlopidine, lithium, anti-TNF agents or methotrexate > 15 mg/week (Note: ASA ≤ 160 mg/day for cardioprotection is permitted), Use of oral or systemic analgesic medication, except from paracetamol, within 3 days of study entry and through the study, Corticosteroids (PO/IM/IV/IA) in the 6 weeks preceding inclusion in the trial, Anti-ulcer medication including chronic (daily or almost daily) use of antacids [Note: Occasional use of antacids during the study will be permitted.]
  • Change in dose of a slow-acting drug (e.g. sulfasalazin, methotrexate) in the past 60 days preceding inclusion in the trial.
  • Taking paracetamol > 2000 mg/day (including during the screening period).

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Dobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Aktiv komparator: Celecoxib 200 milligrams mg QD
celecoxib 200 milligrams (mg) once a day (QD)
Medicin: Celecoxib 200 milligrams
Celecoxib 200 milligrams once a day
Aktiv komparator: Celexocib 400 mg QD
celecoxib 400 milligrams (mg) once a day (QD)
Medicin: Celecoxib 400 milligrams
Celecoxib 400 milligrams once a day
Aktiv komparator: Diclofenac 50 mg TID
diclofenac 50 milligrams (mg) three times a day (TID)
Medicin: diclofenac 50 milligrams
diclofenac 50 milligrams three times a day

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change in baseline of Patient Global Assessment of Pain Intensity (VAS) at week 12
Tidsramme: Baseline, Week 12
Global Pain Intensity score (VAS): is a participant reported assessment of pain on a 0 to 100 millimeter (mm) Visual Analog Scale (VAS) where 0 mm= no pain and 100=most severe pain.
Baseline, Week 12

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Participants Global Assessment of Pain Intensity (VAS)
Tidsramme: Weeks 2, 6
Global Pain Intensity score (VAS): is a participant reported assessment of pain on a 0 to 100 millimeter (mm) Visual Analog Scale (VAS) where 0 mm= no pain and 100=most severe pain.
Weeks 2, 6
Bath Ankylosing Spondylitis Functional Index (BASFI)
Tidsramme: Weeks 2, 6
BASFI is a validated self assessment tool that determines the degree of functional limitation in AS. Utilizing a VAS of 0-10 (0 = easy, 10 = impossible), participants answered 10 questions assessing their ability in completing normal daily activities or physically demanding activities. The BASFI score is a mean score of the 10 questions.
Weeks 2, 6
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)
Tidsramme: Weeks 2, 6
BASDAI is a validated self assessment tool used to determine disease activity in participant with Ankylosing Spondylitis (AS). Utilizing a Visual Analog Scale (VAS) of 0-10 (0=none and 10=very severe) participant's answered 6 questions measuring discomfort, pain and fatigue. The final BASDAI score averages the individual assessments for a final score range of 0-10
Weeks 2, 6
Participants and Physicians Global Assessment of Disease Activity
Tidsramme: Weeks 2, 6, 12
Participants are asked at each visit the following questions: Taking everything into account how do you assess the activity of your disease in the last 2 days on a scale where: 0=disease inactive with no symptoms and 100=disease extremely active?
Weeks 2, 6, 12
Participants and Physicians Global Assessment of Treatment
Tidsramme: Week 12
The patients will be asked up to four global questions about safety and efficacy of the trial medication and about their current disease status. Responses are done on a 5 point scale where 0=no effect, 1=poor effect, 2=moderate effect, 3=good effect, and 4=excellent. At the same visits the investigator will be asked to do his/her own judgment of the efficacy and tolerance of the treatment (excellent, good, moderate, poor).
Week 12
Participants Consumption of Rescue Medication
Tidsramme: Baseline, Weeks 2, 6, 12
Participant consumption of rescue medication (paracetamol) calculated at each individual visit (except from the screening visit) by counting returned tablets versus tablets dispensed at the previous visit.
Baseline, Weeks 2, 6, 12

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Pfizer

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart

1. september 2002

Primær færdiggørelse (Faktiske)

1. november 2004

Studieafslutning (Faktiske)

1. november 2004

Datoer for studieregistrering

Først indsendt

18. juni 2015

Først indsendt, der opfyldte QC-kriterier

18. august 2015

Først opslået (Skøn)

19. august 2015

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Skøn)

19. august 2015

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

18. august 2015

Sidst verificeret

1. august 2015

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • COXA-0508-247
  • A3191099 (Anden identifikator: Alias Study Number)

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Ankyloserende spondylitis

Kliniske forsøg med Celecoxib 200 milligrams

Søg i lignende forsøg

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

CROs by country

CROs in Jamaica

Betingelser

Sjældne sygdomme

Narkotikainterventioner

Kosttilskud

Sponsor / samarbejdspartnere

Placeringer

Abonner